02:31 PM EDT, 10/24/2024 (MT Newswires) -- Monopar Therapeutics ( MNPR ) agreed to acquire the worldwide rights to ALXN-1840, a drug for Wilson disease that has successfully completed a Phase 3 trial, from a division of AstraZeneca (AZN).

Shares of Monopar more than quadrupled as intraday volume topped 12.1 million shares versus the daily average of about 825,000.

Nxu (NXU) agreed to acquire Verde Bioresins in an all-stock transaction.

Shares of Nxu more than doubled as volume topped 373.1 million versus the daily average of almost 263,000.

Tesla's (TSLA) shares surged 21%, a day after the company posted a surprise gain in Q3 earnings and issued a bullish outlook on 2025 volume growth.

Volume topped 152.5 million versus the daily average of 77.4 million.

Price: 21.02, Change: +16.39, Percent Change: +354.00